Newsletter
Newsletter Support JNS

Navy commander says officers wanted strong strikes against Houthis; superiors refused

Rear Adm. Marc Miguez: “It’ll be up to our National Command Authority to probably be more aggressive with our strike groups and all of our assets, not just Navy.”

Dwight D. Eisenhower Carrier Strike Group
The USS Dwight D. Eisenhower Carrier Strike Group steams in formation with the Wasp Amphibious Ready Group and the Royal Navy Daring-class air-defense destroyer “HMS Duncan” in the Mediterranean Sea, June 30, 2024. Credit: Mass Communication Specialist 2nd Class Merissa Daley/U.S. Navy.

A military leader who served on the USS Dwight D. Eisenhower Carrier Strike Group in conflicts against the Iranian-backed Houthis in Yemen stated that high command rejected requests for heavier attacks against the terrorists.

“There are definite strategies that were put forward,” Rear Adm. Marc Miguez told military veteran Ward Carroll in a YouTube interview released on Monday. “But our National Command Authority decided that those—I would call more aggressive postures and more aggressive strikes—was not something we wanted to challenge.”

Miguez noted the widespread knowledge of Iran’s support for the Houthis, saying “that is the calculus that’s handled at echelon zero, at the National Command Authority, with NSA and everybody else.”

According to Miguez, the carrier strike group attacked the Houthis seven times between October and June. “It’ll be up to our National Command Authority to probably be more aggressive with our strike groups and all of our assets, not just Navy,” he said.

“I remain deeply concerned and very troubled by the unacceptable spike in hate crimes, particularly driven by those targeting Jewish New Yorkers,” New York City Council speaker Julie Menin told JNS.
Ambassador Michel Issa warned that implementing the June framework requires careful work to protect civilians.
Two members of the trip-hop group displayed an unauthorized emblem during a concert, which prompted a police investigation.
Rather than target amyloid plaques, the potential new treatment aims to restore immune functions that naturally decline with age.